Anti-inflammation
Fucoidans have been well studied for their anti-inflammatory properties (Apostolova, 2020). Global research demonstrates their extensive potential in addressing both systemic and local inflammation when orally ingested (Fitton, 2015; Fitton, 2019; Apostolova, 2020). Fucoidans can also benefit skin health when applied topically and hold potential in combatting common inflammatory skin conditions (Park, 2021).
Research has shown that fucoidans can:
- Down regulate signalling pathways and decrease the production of pro-inflammatory cytokines (Apostolova, 2020; Selim, 2023; Shanmugasundaram, 2024).
- Block lymphocyte adhesion and invasion (Apostolova, 2020).
- Inhibit selectins and block leucocytes (Fitton, 2015; Fitton, 2019).
- Increase anti-inflammatory proteins (Wang, 2023).
- Inhibit multiple inflammatory enzymes (Lim, 2015; Li, 2020).
Fucoidans produced by Marinova
Studies have shown that high purity fucoidans produced by Marinova can reduce inflammation in the gut (Lean, 2015; Selim, 2023) and reduce the symptoms of osteoarthritis (Myers, 2010). Fucoidans have also been shown to impart anti-inflammatory benefits in a neurological study (Li, 2020), suggesting a potential future in the context of depressive disorders. A 2020 clinical study by Gueven et al. confirmed previous data, showing that high purity fucoidan from Undaria pinnatifida can affect the expression of genes related to fundamental cellular processes, including inflammation.
Inflammation is frequently observed in benign hyperplasia patients and can lead to tissue damage. A recent study demonstrated that Marinova's Undaria pinnatifida fucoidan effectively reduced the expression of dihydrotestosterone, PSA levels, IL-β, TNF-α, and prostate weight. It also preserved the morphology of the prostate tissue through mechanisms involving anti-inflammation, downregulation of dihydrotestosterone, and pro-apoptotic activity in an animal model (Shanmugasundaram, 2024).
Marinova’s fucoidans have been shown to be promising agents for the future management of chronic inflammatory skin conditions such as atopic dermatitis and acne (Park, 2021).